Comparative Pharmacology
Head-to-head clinical analysis: ILEVRO versus OCUFEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ILEVRO versus OCUFEN.
ILEVRO vs OCUFEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nepafenac is a prodrug that is metabolized to amfenac, a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) activity, reducing prostaglandin synthesis.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis, thereby decreasing intraocular inflammation and pain.
1 drop of the 0.3% ophthalmic solution administered to the affected eye(s) four times daily.
1 drop of 0.03% solution in the affected eye(s) four times daily beginning 24 hours after cataract surgery.
None Documented
None Documented
Terminal elimination half-life of amfenac is approximately 0.7 hours in plasma, but due to prolonged residence in ocular tissues, the clinical effect lasts up to 24 hours with once-daily dosing.
1.2 to 2.0 hours (topical administration in ocular tissues); systemic half-life is 1.1 to 1.4 hours.
Nepafenac is extensively metabolized, and its active metabolite amfenac is primarily excreted renally (approximately 80% as metabolites, including amfenac glucuronide, and 20% as unchanged drug in urine). Biliary/fecal excretion accounts for less than 10%.
Urinary excretion of unchanged drug accounts for approximately 82% of a topical dose; fecal excretion is minor (<5%).
Category C
Category C
Ophthalmic NSAID
Ophthalmic NSAID